Mary K. Olson : Citation Profile


Are you Mary K. Olson?

Tulane University

7

H index

5

i10 index

100

Citations

RESEARCH PRODUCTION:

14

Articles

1

Papers

RESEARCH ACTIVITY:

   29 years (1992 - 2021). See details.
   Cites by year: 3
   Journals where Mary K. Olson has often published
   Relations with other researchers
   Recent citing documents: 6.    Total self citations: 9 (8.26 %)

MORE DETAILS IN:
ABOUT THIS REPORT:

   Permalink: http://citec.repec.org/pol152
   Updated: 2024-12-03    RAS profile: 2022-12-30    
   Missing citations? Add them    Incorrect content? Let us know

Relations with other researchers


Works with:

Authors registered in RePEc who have co-authored more than one work in the last five years with Mary K. Olson.

Is cited by:

Philipson, Tomas (6)

Bailey, James (5)

Markowitz, Sara (3)

Gaulé, Patrick (3)

Sun, Eric (3)

Söderberg, Magnus (3)

Richards-Shubik, Seth (3)

Agarwal, Ruchir (3)

Earnhart, Dietrich (2)

Law, Marc (2)

Salin, Victoria (2)

Cites to:

Joskow, Paul (8)

Weingast, Barry (5)

peltzman, sam (5)

Kyle, Margaret (3)

Viscusi, W (3)

Dranove, David (3)

Philipson, Tomas (3)

Yin, Wesley (2)

Cockburn, Iain (2)

Noll, Roger (2)

DiMasi, Joseph (2)

Main data


Where Mary K. Olson has published?


Journals with more than one article published# docs
The Journal of Law, Economics, and Organization3
Journal of Economics & Management Strategy2
Journal of Health Economics2

Recent works citing Mary K. Olson (2024 and 2023)


YearTitle of citing document
2023Pharmaceuticals, incremental innovation and market exclusivity. (2023). Yin, Nina. In: International Journal of Industrial Organization. RePEc:eee:indorg:v:87:y:2023:i:c:s0167718723000048.

Full description at Econpapers || Download paper

2024Regulating ethical experimentation: Impacts of the breakthrough therapy designation on drug R&D. (2024). Hermosilla, Manuel. In: Journal of Health Economics. RePEc:eee:jhecon:v:94:y:2024:i:c:s0167629623001327.

Full description at Econpapers || Download paper

Works by Mary K. Olson:


YearTitleTypeCited
1997Firm Characteristics and the Speed of FDA Approval In: Journal of Economics & Management Strategy.
[Full Text][Citation analysis]
article14
2000Regulatory Reform and Bureaucratic Responsiveness to Firms: the Impact of User Fees in the FDA In: Journal of Economics & Management Strategy.
[Full Text][Citation analysis]
article2
2004Are novel drugs more risky for patients than less novel drugs? In: Journal of Health Economics.
[Full Text][Citation analysis]
article17
2008The risk we bear: The effects of review speed and industry user fees on new drug safety In: Journal of Health Economics.
[Full Text][Citation analysis]
article15
1992Pharmaceutical Expenditure and Regulatory Policy in the NHS. In: Washington St. Louis - School of Business and Political Economy.
[Citation analysis]
paper0
2013Eliminating the U.S. drug lag: Implications for drug safety In: Journal of Risk and Uncertainty.
[Full Text][Citation analysis]
article2
1994Political Influence and Regulatory Policy: The 1984 Drug Legislation. In: Economic Inquiry.
[Citation analysis]
article1
1995Regulatory Agency Discretion among Competing Industries: Inside the FDA. In: The Journal of Law, Economics, and Organization.
[Citation analysis]
article11
1996Substitution in Regulatory Agencies: FDA Enforcement Alternatives. In: The Journal of Law, Economics, and Organization.
[Citation analysis]
article8
1999Agency Rulemaking, Political Influences, Regulation, and Industry Compliance. In: The Journal of Law, Economics, and Organization.
[Citation analysis]
article7
1995The Effects of UK Pharmaceutical Policy on Government Drug Expenditure: Cost Control and Incentives for R&D In: International Journal of the Economics of Business.
[Full Text][Citation analysis]
article1
2018Examining Firm Responses to R&D Policy: An Analysis of Pediatric Exclusivity In: American Journal of Health Economics.
[Full Text][Citation analysis]
article6
2018Examining Firm Responses to R&D Policy: An Analysis of Pediatric Exclusivity.(2018) In: American Journal of Health Economics.
[Full Text][Citation analysis]
This paper has nother version. Agregated cites: 6
article
2002Pharmaceutical Policy Change and the Safety of New Drugs In: Journal of Law and Economics.
[Full Text][Citation analysis]
article15
2021New clinical information and physician prescribing: How do pediatric labeling changes affect prescribing to children? In: Health Economics.
[Full Text][Citation analysis]
article1

CitEc is a RePEc service, providing citation data for Economics since 2001. Last updated November, 3 2024. Contact: CitEc Team